Tuberculosis is a major health care problem in the developing world. According to the WHO, a total of 9,400,000 new cases were diagnosed throughout the world in 2010. 30% of these cases were diagnosed in Africa whereas 35% were detected in South East Asia. The disease resulted in 1,300,000 deaths in 2010. People with decreased immunity are particularly susceptible, especially those with HIV. Resistance to anti-tuberculosis treatment also adds to the problem.
Who should undergo screening for tuberculosis?
People at high risk of contacting tuberculosis are advised to undergo screening for the disease. These include:
- People living or working in close contact with tuberculosis patients
- HIV patients and other people with decreased immunity
- People living in areas where tuberculosis is very common i.e. most countries in Africa, Asia, Latin America and the Caribbean, Eastern Europe, and Russia
- People living under conditions where tuberculosis spreads easily e.g. prisons
- Drug addicts who inject drugs
Which tests are used for screening for tuberculosis?
Tests used to screen persons for tuberculosis include the tuberculin skin test and the Interferon – Release Assays
Tuberculin Skin Test (TST): Tuberculin skin test is also called as the Mantoux test, Pirquet test or the PPD test. In this test, a small test dose is injected between the layers of the skin (intrdermally) and the area is marked. After 48 to 72 hours, the area is checked for any induration (hard swelling).
- An induration of more than 10 mm indicates a positive test and is seen in patients exposed to the tuberculosis bacteria.
- An induration of more than 5 mm may be considered positive in patients with HIV or low immunity.
- False negative reactions occur in people with low immunity or with severe infection.
- False positive reactions may occur in patients with prior BCG vaccination and patients with infections caused by non tubercular mycobacteria.
Interferon - Release Assays: These are blood tests used to detect tuberculosis. When the blood of patients is incubated with certain proteins of TB bacteria, the immune cells from the patient’s blood release a substance called interferon. This is detected during these tests. Tests that are commercially available include the QuantiFERON – TB Gold, QuantiFERON-TB Gold In-Tube test (QFT-GIT) and T.SPOT.TB test.
False positive reactions in patients with BCG vaccination or with infections caused by non tubercular mycobacteria are less likely to occur with these tests.
These tests require less frequent visits to the hospital and results are available within 24 hours.
They do not require measurement of skin induration, which could be highly subjective and lead to errors.
They are highly specific for tuberculosis. In addition, they do not boost responses to subsequent tests. These tests may not be preferred in children less than 5 years. They are also more expensive.
Frequently Asked Questions
1. When should I call a doctor?
A consultation with your physician or tuberculosis specialist is advised if the results of the above tests come as abnormal.
2. What is meant by false positive and false negative test?
A false positive test means that the test has turned positive despite the patient not suffering from the disease. A false negative test means that the person suffers from the disease, yet the test has given a negative result.
3. Which of the above test is preferred?
The blood tests are preferred over the tuberculin test. However, they are expensive and may not be feasible to be carried out on a large number of people especially in the underdeveloped countries. They should also not be conducted in children less than 5 years.
4. My tuberculin test shows a red area but no induration. Is it positive?
No. Induration is necessary to read the test as positive.
Latest Publications and Research on Screening Tests for Tuberculosis
- Foreign background and older age of children were associated with infection in Swedish tuberculosis contacts. - Published by PubMed
- Rehabilitation, optimized nutritional care and boosting host internal milieu to improve long-term treatment outcomes in TB patients. - Published by PubMed
- Differential antigen recognition by serum antibodies from three bovid hosts of Mycobacterium bovis infection. - Published by PubMed
- Case Report of Kikuchi-Fujimoto Disease from Sub-Saharan Africa: An Important Mimic of Tuberculous Lymphadenitis. - Published by PubMed
- Comparative results of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus assays for tuberculosis diagnosis of clinical samples. - Published by PubMed
Do you wish to consult a General Medicine Doctor / Internal Medicine Doctor for your problem? Ask your question
3 years experience
Christ, Madhapar, Rajkot
5 years experience
1 year experience
12 years experience